|
Apr 15
|
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
|
|
Apr 14
|
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
|
|
Feb 14
|
Fate Therapeutics to Present at Upcoming Investor Conferences
|
|
Jan 3
|
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
|